[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100055020":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":7,"locations":14,"responsibleParty":7,"collaborators":7,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":7,"eligibilityCriteria":72,"healthyVolunteers":69,"sex":73,"minAge":74,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":85,"whyStopped":7,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":90,"locationsCount":92},{"fullName":5,"class":6},"NIH AIDS Clinical Trials Information Service","INDUSTRY",null,[9,12],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","Nystatin",{"type":10,"name":13,"description":7,"armGroupLabels":7,"otherNames":7},"Fluconazole",[15,28,37,47,57],{"facility":16,"status":7,"city":17,"state":18,"zip":19,"country":20,"countryCode":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":7},"California Med Research Group","Fresno","California","93726","United States","US",{"type":23,"coordinates":24},"Point",[25,26],-119.77237,36.74773,{"lat":26,"lon":25},{"facility":29,"status":7,"city":30,"state":18,"zip":31,"country":20,"countryCode":21,"cosmosGeoPoint":32,"geoPoint":36,"contacts":7},"UCSF Hosp","San Francisco","94143",{"type":23,"coordinates":33},[34,35],-122.41942,37.77493,{"lat":35,"lon":34},{"facility":38,"status":7,"city":39,"state":40,"zip":41,"country":20,"countryCode":21,"cosmosGeoPoint":42,"geoPoint":46,"contacts":7},"Johns Hopkins School of Medicine","Baltimore","Maryland","21205",{"type":23,"coordinates":43},[44,45],-76.61219,39.29038,{"lat":45,"lon":44},{"facility":48,"status":7,"city":49,"state":50,"zip":51,"country":20,"countryCode":21,"cosmosGeoPoint":52,"geoPoint":56,"contacts":7},"Med College of Pennsylvania","Philadelphia","Pennsylvania","19129",{"type":23,"coordinates":53},[54,55],-75.16362,39.95238,{"lat":55,"lon":54},{"facility":58,"status":7,"city":59,"state":60,"zip":61,"country":20,"countryCode":21,"cosmosGeoPoint":62,"geoPoint":66,"contacts":7},"Hampton Roads Med Specialists","Hampton","Virginia","23666",{"type":23,"coordinates":63},[64,65],-76.34522,37.02987,{"lat":65,"lon":64},"100055020","comparative-randomized-study-of-the-efficacy-safety-and-toleration-of-fluconazole-oral-suspension-or-nystatin-oral-suspension-in-the-treatment-of-patients-with-oropharyngeal-candidiasis-in-association-with-the-acquired-immunodeficiency-syndrome-100055020",false,"NCT00002112","Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome","Inclusion Criteria\n\nConcurrent Medication:\n\nAllowed:\n\n* Phenytoin.\n* Oral hypoglycemics.\n* Coumarin-type anticoagulants.\n* Cyclosporine.\n\nPatients must have:\n\n* ARC or AIDS.\n* Signs of oropharyngeal candidiasis (i.e., typical white plaques) with some associated symptoms.\n* Confirmation of diagnosis by microscopic exam and culture of organism.\n* Life expectancy of at least 4 weeks.\n\nNOTE:\n\n* Patients with signs or symptoms of esophagitis (e.g., odynophagia) are not eligible unless esophagoscopy is performed and results are negative.\n\nExclusion Criteria\n\nCo-existing Condition:\n\nPatients with the following conditions are excluded:\n\n* Unable to tolerate oral medication.\n* Concurrent enrollment on another experimental trial of approved or non-approved drugs or systemic compounds (without approval of Pfizer clinical monitor).\n\nConcurrent Medication:\n\nExcluded:\n\n* Antifungal agents other than study drugs.\n* Other experimental medications.\n\nPatients with the following prior conditions are excluded:\n\nKnown history of intolerance or allergy to imidazoles or triazoles or the polyene components of nystatin.\n\nPrior Medication:\n\nExcluded:\n\n* Other antifungal agents within the past 3 days.","ALL","13 Years","INTERVENTIONAL",[77],"NA","To compare the efficacy, safety, and toleration of fluconazole as a single daily oral suspension for 14 days versus nystatin oral suspension 4 times daily for 14 days in the treatment of oropharyngeal candidiasis in patients with AIDS or HIV infection.",[80,81],"Candidiasis, Oral","HIV Infections",[11,13,83,84,80],"Acquired Immunodeficiency Syndrome","AIDS-Related Complex","COMPLETED","2005-06-23",{"date":88,"type":89},"2005-06-24","ESTIMATED",{"name":91,"class":6},"Pfizer",5]